A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-Positive Early Breast Cancer
Interventions: DRUG: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|DRUG: Pertuzumab IV|DRUG: Trastuzumab IV
Sponsor: Hoffmann-La Roche